Kalaris Therapeutics, Inc. (KLRS) Total Assets by Year
Kalaris Therapeutics, Inc. closed fiscal year 2025 with $121.7M in total assets, $42.9M in total liabilities and $78.8M in shareholder equity. This represents an increase of 1875.6% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Kalaris Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
KLRS Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY25DEF 14A | FY24DEF 14A | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K |
|---|---|---|---|---|---|---|---|
| Total Assets | $121.7M+1875.6% | $6.2M-96.8% | $190.8M-31.1% | $277.1M-3.3% | $286.6M-22.7% | $370.8M+166.0% | $139.4M |
| Total Liabilities | $42.9M-58.2% | $102.8M-56.4% | $235.8M+348.7% | $52.6M-14.3% | $61.3M+245.4% | $17.8M-90.7% | $190.9M |
| Total Equity | $78.8M+181.6% | -$96.6M-114.6% | -$45.0M-120.1% | $224.5M-0.3% | $225.3M-36.2% | $353.1M+785.5% | -$51.5M |
KLRS Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $99.5M+7.2% | $109.8M+6.5% | $121.7M+1875.6% | $81.2M-33.8% | $92.8M-29.1% | $103.1M-28.5% | $6.2M-96.8% | $122.5M-50.7% | $131.0M-53.7% | $144.1M-40.9% | $190.8M-31.1% | $248.3M-15.5% |
| Total Liabilities | $41.9M+5.4% | $41.2M+5.2% | $42.9M-58.2% | $39.3M-81.4% | $39.7M-78.2% | $39.2M-79.5% | $102.8M-56.4% | $211.9M+300.0% | $182.5M+240.6% | $191.7M+279.5% | $235.8M+348.7% | $53.0M+30.9% |
| Total Equity | $57.7M+8.6% | $68.6M+7.3% | $78.8M+181.6% | $41.9M+146.8% | $53.1M+203.1% | $63.9M+234.4% | -$96.6M-114.6% | -$89.4M-145.8% | -$51.5M-122.5% | -$47.5M-124.6% | -$45.0M-120.1% | $195.3M-22.9% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Kalaris Therapeutics, Inc. financials
Frequently Asked Questions
What was Kalaris Therapeutics, Inc.'s total assets in fiscal year 2025?
Kalaris Therapeutics, Inc. closed fiscal year 2025 with $121.7M in total assets, $42.9M in total liabilities and $78.8M in shareholder equity.
How fast is Kalaris Therapeutics, Inc.'s total assets growing?
Kalaris Therapeutics, Inc. (KLRS) total assets rose by 1875.6% year over year, from $6.2M to $121.7M in fiscal year 2025.
How has Kalaris Therapeutics, Inc.'s total assets changed over the years?
Across the 7 fiscal years this page covers, Kalaris Therapeutics, Inc. (KLRS) total assets went from $139.4M in fiscal year 2019 to $121.7M in fiscal year 2025.
What was Kalaris Therapeutics, Inc.'s total assets in the most recent quarter?
Kalaris Therapeutics, Inc. (KLRS) reported $99.5M in total assets in Q2 2026. This represents an increase of 7.2% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Kalaris Therapeutics, Inc. (KLRS) reported on that line in every period on record.